2025 AF Symposium New Report: Weight Loss Drugs and A-Fib
Many A-Fib patients are overweight and also suffer from sleep apnea and hypertension.
At the 2025 AF Symposium, Dr. Donna Ryan of Louisiana State University, Baton Rouge, Louisiana gave a talk on GLP-1 Agonists and their role in treating A-Fib.
She offers insight into how obesity affects a patient’s Atrial Fibrillation. And how today’s GLP-1 agonists (like brand names Ozempic, Mounjaro and Victoza) may go beyond helping with weight loss and can also help improve sleep apnea and/or high blood pressure.
To read my new report, go to: Weight Loss Drugs and A-Fib

GLP-1 Agonist Medications






